Skip to main content

Table 1 Effects of diazoxide treatment on clinical signs during the effector phase of EAE mice

From: Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis

 

N° animals

  

Mean clinical score

Area under the curve (AUC)

 
  

N° EAE death

Days of treatment

Mean

Maximal grade

 

Vehicle

      

   Exp 1

11

1

15

3.1 ± 0.1

4.1 ± 0.4

43.9 ± 4.7

   Exp 2

8

0

15

3.3 ± 0.2

4.4 ± 0.1

48.3 ± 2.0

   Exp 3

7

1

15

3.5 ± 0.2

4.7 ± 0.2

56.0 ± 4.4

Diazoxide

      

   Exp 1

11

0

15

1.9 ± 0.1***

2.7 ± 0.3*

28.3 ± 4.4*

   Exp 2

9

0

15

2.6 ± 0.1**

3.8 ± 0.2*

37.2 ± 3.1*

   Exp 3

7

0

15

2.6 ± 0.1***

3.5 ± 0.5*

36.9 ± 5.1*

  1. Summary of three independent experiments. During the effector phase of EAE, 0.8 mg/kg diazoxide significantly reduced the mean global score, maximal grade and area under the curve when compared to untreated mice. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.